Ernexa Therapeutics (ERNA) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Ernexa Therapeutics (ERNA) over the last 10 years, with Q3 2025 value amounting to -$0.15.
- Ernexa Therapeutics' EPS (Weighted Average and Diluted) rose 9979.65% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $103.28, marking a year-over-year increase of 21298.55%. This contributed to the annual value of -$3.26 for FY2024, which is 1999.05% up from last year.
- According to the latest figures from Q3 2025, Ernexa Therapeutics' EPS (Weighted Average and Diluted) is -$0.15, which was up 9979.65% from -$0.61 recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.15 during Q1 2025, and its lowest value of -$73.7 during Q3 2024.
- Over the past 5 years, Ernexa Therapeutics' median EPS (Weighted Average and Diluted) value was -$1.16 (recorded in 2023), while the average stood at -$8.18.
- Per our database at Business Quant, Ernexa Therapeutics' EPS (Weighted Average and Diluted) plummeted by 4040237.73% in 2021 and then surged by 9979.65% in 2025.
- Over the past 5 years, Ernexa Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$34.03 in 2021, then surged by 95.67% to -$1.47 in 2022, then grew by 21.34% to -$1.16 in 2023, then surged by 63.55% to -$0.42 in 2024, then soared by 64.5% to -$0.15 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.15 for Q3 2025, versus -$0.61 for Q2 2025 and -$0.15 for Q1 2025.